DCT

1:24-cv-09729

Novo Nordisk Inc v. Apotex Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-09729, D.N.J., 06/23/2026
  • Venue Allegations: Venue is based on allegations that Defendant Apotex intends to market and sell its generic products throughout the United States, including within the District of New Jersey, and has previously consented to personal jurisdiction in the district in other matters.
  • Core Dispute: Plaintiff alleges that Defendant’s submission of Abbreviated New Drug Applications (ANDAs) to the FDA for generic versions of Plaintiff's Rybelsus®, Ozempic®, and Wegovy® products constitutes an act of infringement of fifteen U.S. patents covering the active ingredient semaglutide, specific pharmaceutical formulations, and methods of use.
  • Technical Context: The technology relates to oral formulations of glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs used to treat type 2 diabetes and obesity that have historically required administration by injection due to poor oral bioavailability.
  • Key Procedural History: This is a consolidated action arising from three separate sets of ANDA filings by Apotex seeking to market generic versions of Novo Nordisk's semaglutide products. For each, Apotex submitted Paragraph IV certifications asserting that the patents listed in the FDA's Orange Book are invalid, unenforceable, and/or will not be infringed by Apotex's proposed generic products. Novo Nordisk filed suit within the statutory 45-day window following receipt of Apotex's notice letters, triggering an automatic 30-month stay on FDA approval of the ANDAs.

Case Timeline

Date Event
2010-12-20 Earliest Priority Date (’123, ’047, ’957 Patents)
2012-03-06 Issue Date (U.S. Patent No. 8,129,343, mentioned as related)
2012-06-23 Earliest Priority Date (’430, ’499 Patents)
2013-01-04 Earliest Priority Date (’120, ’501, ’502, ’503, ’326 Patents)
2013-05-02 Earliest Priority Date (’923, ’822 Patents)
2013-09-17 Issue Date (U.S. Patent No. 8,536,122, mentioned as related)
2016-03-08 Issue Date ('123 Patent)
2018-02-02 Earliest Priority Date (’248, ’953 Patents)
2018-06-12 Issue Date ('430 Patent)
2018-10-02 Issue Date ('047 Patent)
2019-05-07 Issue Date ('923 Patent)
2021-03-02 Issue Date ('120 Patent)
2021-03-30 Issue Date (’052 Patent)
2021-06-15 Issue Date ('499 Patent)
2022-07-12 Issue Date ('957 Patent)
2023-09-19 Issue Date ('501, '502, '503 Patents)
2023-12-05 Issue Date ('248 Patent)
2024-08-29 Apotex Notice Letter re: Rybelsus® ANDA (Compl. ¶34)
2024-11-21 Apotex Second Notice Letter re: Rybelsus® ANDA (Compl. ¶34)
2025-06-20 Apotex Third Notice Letter re: Rybelsus® ANDA (Compl. ¶34)
2025-08-26 Issue Date ('953 Patent)
2026-01-06 Issue Date ('822 Patent)
2026-01-30 Apotex Notice Letter re: Ozempic® ANDA (Compl. ¶45)
2026-04-07 Issue Date ('326 Patent)
2026-04-29 Apotex Notice Letter re: Wegovy® ANDA (Compl. ¶55)
2026-05-07 '499 Patent listed in Orange Book (Compl. ¶38; Compl. ¶47)
2026-06-16 Court Order referenced in Complaint (Compl. ¶38)
2026-06-23 Complaint Filing Date (Compl. p. 1)

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,278,123 - Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-hydroxybenzoyl)Amino)Caprylic Acid

  • Patent Identification: U.S. Patent No. 9,278,123, Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-hydroxybenzoyl)Amino)Caprylic Acid, issued March 8, 2016.

The Invention Explained

  • Problem Addressed: The patent addresses the "low oral bioavailability" of human glucagon-like peptide-1 (GLP-1) and its analogues, which are therapeutic proteins for treating diabetes (Compl. ¶67; '123 Patent, col. 1:29-31). This poor absorption has historically limited their administration to injections.
  • The Patented Solution: The invention is a solid pharmaceutical composition for oral administration that combines a GLP-1 agonist with a specific delivery agent, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (commonly known as SNAC) ('123 Patent, abstract). This combination is designed to facilitate the absorption of the large-molecule GLP-1 drug through the gastrointestinal tract into the bloodstream ('123 Patent, col. 2:4-13).
  • Technical Importance: The successful oral delivery of a peptide drug like a GLP-1 agonist represented a significant advancement in patient convenience for diabetes and obesity management, shifting treatment away from injections.

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 and/or claim 9, depending on the accused product (Compl. ¶124; Compl. ¶425; Compl. ¶582). Claim 1 is the asserted independent claim for the Rybelsus® generic.
  • The essential elements of independent claim 1 are:
    • A solid composition for oral administration comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid,
    • wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is at least 0.8 mmol, and
    • wherein the GLP-1 agonist is N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37) (semaglutide).
  • The complaint reserves the right to assert infringement of one or more claims of the patent (Compl. ¶39).

U.S. Patent No. 9,993,430 - Tablet Formulation Comprising Semaglutide and a Delivery Agent

  • Patent Identification: U.S. Patent No. 9,993,430, Tablet Formulation Comprising Semaglutide and a Delivery Agent, issued June 12, 2018.

The Invention Explained

  • Problem Addressed: The patent seeks to provide "further improvements" to oral GLP-1 compositions, building on the initial concept of combining semaglutide with a delivery agent like SNAC ('430 Patent, col. 1:33-36).
  • The Patented Solution: The patent claims a specific tablet with defined physical properties. It describes a tablet made from a granulate containing semaglutide and SNAC, where the final tablet possesses specific characteristics including a high bulk density, small pore diameters, a minimum crushing strength, and a narrow disintegration time window ('430 Patent, abstract; '430 Patent, col. 2:19-38). These physical attributes are presented as key to achieving the desired drug release and absorption profile.
  • Technical Importance: This technology focuses on the manufacturing process and final form of the dosage, suggesting that the physical structure of the tablet itself, not just its chemical components, is critical for enabling oral bioavailability.

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 of the patent (Compl. ¶136; Compl. ¶145).

  • The essential elements of independent claim 1 are:

    • A tablet comprising a granulate comprising no more than 15% (w/w) semaglutide and at least 50% (w/w) salt of NAC;
    • wherein said tablet has a bulk density of at least 1.0 g/cm³;
    • a median pore diameter of no more than 1.5 µm;
    • a maximum pore diameter of no more than 4 µm;
    • a crushing strength of at least 50 N; and
    • a disintegration time of 12-18 minutes for a tablet with a total weight of 300-500 mg comprising at least 60% (w/w) salt of NAC.

  • The complaint reserves the right to assert infringement of one or more claims of the patent (Compl. ¶136).

  • Multi-Patent Capsule: U.S. Patent No. 10,086,047

    • Patent Identification: U.S. Patent No. 10,086,047, Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid, issued October 2, 2018 (Compl. ¶73).
    • Technology Synopsis: This patent relates to solid oral compositions of a GLP-1 agonist (such as semaglutide) and the delivery agent SNAC. The claims focus on specific molar ratios of the components and a particular disintegration time of 7-15 minutes, which are purported to improve bioavailability ('047 Patent, abstract; '047 Patent, claim 1).
    • Asserted Claims: At least claim 1 (Compl. ¶162).
    • Accused Features: Apotex's proposed generic for Rybelsus®, which is alleged to copy the composition and properties of the branded product (Compl. ¶165).

  • Multi-Patent Capsule: U.S. Patent No. 10,278,923

    • Patent Identification: U.S. Patent No. 10,278,923, Oral Dosing of GLP-1 Compounds, issued May 7, 2019 (Compl. ¶76).
    • Technology Synopsis: This patent claims methods for treating type 2 diabetes or obesity by orally administering a composition comprising a GLP-1 peptide (like semaglutide) that has a long plasma half-life (at least 60 hours). The invention centers on the relationship between the drug's long half-life and the dosing interval, claiming a specific ratio of more than 2:1 between the two ('923 Patent, abstract; '923 Patent, claim 14).
    • Asserted Claims: At least claim 14 (Compl. ¶183).
    • Accused Features: The proposed label for Apotex's generics, which allegedly instructs administration in a manner that infringes the claimed method of treatment (Compl. ¶195).

  • Multi-Patent Capsule: U.S. Patent No. 10,933,120

    • Patent Identification: U.S. Patent No. 10,933,120, Compositions of GLP-1 Peptides and Preparation Thereof, issued March 2, 2021 (Compl. ¶79).
    • Technology Synopsis: This patent covers solid dosage pharmaceutical compositions made of two different types of granules. The first type contains the delivery agent SNAC but no GLP-1 peptide, while the second type contains the GLP-1 peptide (semaglutide), a filler, a binder, and no SNAC ('120 Patent, abstract). This separation of components into different granules is the distinguishing feature.
    • Asserted Claims: At least claim 1 (Compl. ¶214).
    • Accused Features: The composition of Apotex's proposed generics, which are alleged to be identical or substantially identical to the branded products that are covered by the patent (Compl. ¶217).

  • Additional Multi-Patent Capsules: The complaint asserts thirteen additional patents, which generally claim further refinements and variations of the formulations, manufacturing methods, and methods of use for oral semaglutide. These include: '052, '499, '957, '501, '502, '503, '248, '953, '822, and '326 patents (Compl. ¶¶81-110).

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Apotex's Abbreviated New Drug Application (ANDA) products seeking FDA approval as generic versions of Novo Nordisk's drugs:

  • ANDA No. 219837 for generic RYBELSUS® (semaglutide) tablets (Compl. ¶29).
  • ANDA No. 221238 for generic OZEMPIC® (semaglutide) tablets (Compl. ¶40).
  • ANDA No. 221537 for generic WEGOVY® (semaglutide) tablets (Compl. ¶50).

Functionality and Market Context

  • The complaint alleges that Apotex's ANDA filings describe pharmaceutical products that are intended to be generic equivalents of Novo Nordisk's blockbuster drugs for type 2 diabetes and/or obesity (Compl. ¶¶4, 11, 17, 23). The active pharmaceutical ingredient in all accused products is semaglutide (Compl. ¶14; Compl. ¶20; Compl. ¶26). The complaint displays the structural formula for semaglutide, which is central to the allegations against all accused products (Compl. ¶14).
  • The act of infringement alleged is the submission of the ANDAs with Paragraph IV certifications under 35 U.S.C. § 271(e)(2), which allows for patent litigation before the generic drug is marketed (Compl. ¶39; Compl. ¶48; Compl. ¶58). The complaint's infringement theory is premised on the allegation that Apotex's proposed products will have the same active ingredient, composition, and dosage instructions as the patented and branded products (Compl. ¶120; Compl. ¶122).

IV. Analysis of Infringement Allegations

The complaint does not contain detailed claim charts mapping specific features of Apotex's proposed products to the patent claims, as is common in ANDA litigation at the pleading stage before discovery of the confidential ANDA contents. The allegations are based on the premise that Apotex's products are copies of Novo Nordisk's products, which are covered by the patents.

'123 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A solid composition for oral administration comprising a GLP-1 agonist... and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid The complaint alleges Apotex’s ANDA No. 219837 product is a solid oral tablet containing the active ingredient semaglutide (a GLP-1 agonist) and the inactive ingredient salcaprozate sodium (SNAC), which is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. ¶115; ¶116; ¶120 col. 9:15-21
wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is at least 0.8 mmol The complaint alleges that Apotex’s product essentially copies the RYBELSUS® composition, which is covered by at least claim 1 of the ’123 Patent, and is therefore alleged to meet this quantitative limitation. ¶117; ¶120 col. 9:55-58
and wherein the GLP-1 agonist is N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37) The complaint identifies the active ingredient in RYBELSUS® as semaglutide and alleges Apotex’s product is a generic version thereof. The claim recites the chemical name for semaglutide. ¶116 col. 24:1-12

'430 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A tablet comprising a granulate comprising no more than 15% (w/w) semaglutide and at least 50% (w/w) salt of... (NAC); Based on Apotex's alleged copying of the RYBELSUS® composition, the complaint alleges the accused product will contain semaglutide and SNAC within the claimed weight percentages. ¶141 col. 2:19-23
wherein said tablet has a bulk density of at least 1.0 g/cm³, The complaint alleges that Apotex’s product is identical or substantially identical to RYBELSUS®, which is asserted to be covered by the patent and therefore possess the claimed physical properties. ¶141; ¶142 col. 2:23-24
a median pore diameter of no more than 1.5 µm, As above, infringement of this physical property is alleged based on the proposed generic being a copy of a product covered by the patent. ¶141; ¶142 col. 2:24-25
a maximum pore diameter of no more than 4 µm, As above, infringement of this physical property is alleged based on the proposed generic being a copy of a product covered by the patent. ¶141; ¶142 col. 2:25-26
a crushing strength of at least 50 N, and As above, infringement of this physical property is alleged based on the proposed generic being a copy of a product covered by the patent. ¶141; ¶142 col. 2:26-27
a disintegration time of 12-18 minutes... As above, infringement of this physical property is alleged based on the proposed generic being a copy of a product covered by the patent. ¶141; ¶142 col. 2:27-31

Identified Points of Contention

  • Factual Scope: The central dispute will be factual and determined through discovery of the ANDA. The key question is whether Apotex’s proposed generic products actually possess the specific compositions and, critically for patents like the '430 Patent, the precise physical parameters (density, porosity, strength, disintegration time) recited in the claims when measured by the methods specified in the patents.
  • Method of Use: For method claims (e.g., in the '923 and '822 patents), a point of contention will be whether the proposed product label for Apotex's generic induces infringement by instructing administration according to the patented dosing regimens.
  • Invalidity: Apotex's Paragraph IV certification asserts that the patents are invalid (Compl. ¶32). The defense will likely argue that the claimed formulations and methods were obvious extensions of prior art knowledge regarding oral drug delivery enhancers and GLP-1 analogues.

V. Key Claim Terms for Construction

  • The Term: "disintegration time" (from '430 Patent, claim 1)
  • Context and Importance: Claim 1 of the '430 Patent requires "a disintegration time of 12-18 minutes." This narrow window is a critical limitation distinguishing the invention. The method used to measure this time will be determinative of infringement, and practitioners may focus on this term because disputes over testing methodologies are common in pharmaceutical patent cases.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue that "disintegration time" should be given its plain and ordinary meaning as understood in the pharmaceutical arts, potentially allowing for various standard measurement techniques. The patent itself references the general concept in the background ('430 Patent, col. 1:33-36).
    • Evidence for a Narrower Interpretation: The patent provides strong evidence for a narrow definition. The specification states that the disintegration time is "determined by the disintegration test described herein" ('430 Patent, col. 8:17-19) and later provides a detailed protocol referencing a specific apparatus (Ph.Eur. 2.9.1 basket-rack), medium, temperature, and procedure ('430 Patent, col. 7:10-12; col. 13:20-33). This suggests the patentee intended to be their own lexicographer for this term.

VI. Other Allegations

Indirect Infringement

The complaint alleges that should Apotex's products be approved, Apotex will induce infringement of method-of-use claims (e.g., '923 Patent) by creating a product label that instructs, encourages, and recommends that physicians and patients administer the drug in the infringing manner (Compl. ¶195). It is also alleged that the products have no substantial non-infringing uses, which could support a claim for contributory infringement (Compl. ¶197).

Willful Infringement

Willfulness is alleged based on Apotex’s pre-suit knowledge of the patents, evidenced by its Paragraph IV certification notice letters sent to Novo Nordisk (Compl. ¶114; Compl. ¶137). The complaint further alleges that Apotex's infringement is "deliberate, willful, and wanton" and that its legal and factual bases for non-infringement or invalidity are "devoid of an objective good faith basis," seeking a finding of an exceptional case under 35 U.S.C. § 285 (Compl. ¶131; Compl. ¶132).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A central issue will be one of compositional and physical identity: Will discovery reveal that Apotex's proposed generic formulations, as described in its confidential ANDA, possess the exact chemical compositions, component ratios, and, for certain patents, the specific physical tablet properties (e.g., density, porosity, disintegration time) claimed by Novo Nordisk?
  • A second key question will be one of invalidity: Can Apotex demonstrate through prior art that Novo Nordisk's claimed formulations and their specific physical parameters were obvious combinations or routine optimizations, rather than a non-obvious solution to the long-standing challenge of creating an orally bioavailable peptide drug?
  • Finally, the case will involve a question of induced infringement: For the method-of-use patents, the court will need to determine if Apotex's proposed product label, by virtue of being a copy of the branded drug's label, necessarily instructs users to perform the patented methods of treatment, thereby making Apotex liable for inducing infringement.
Loading Amended Complaint